Rhumbline Advisers boosted its holdings in shares of Atara Biotherapeutics, Inc. (NASDAQ: ATRA – Get Rating) by 1.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 128,089 shares of the biotechnology company stock after buying an additional 2,052 shares during the quarter. Rhumbline Advisers owned approximately 0.14% of Atara Biotherapeutics worth $ 2,019,000 as of its most recent SEC filing.
A number of other hedge funds have also modified their holdings of the stock. DekaBank Deutsche Girozentrale increased its holdings in Atara Biotherapeutics by 2.9% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 28,400 shares of the biotechnology company stock valued at $ 476,000 after buying an additional 800 shares during the period. Teacher Retirement System of Texas boosted its stake in Atara Biotherapeutics by 19.8% in the fourth quarter. Teacher Retirement System of Texas now owns 13,719 shares of the biotechnology company stock valued at $ 216,000 after acquiring an additional 2,268 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Atara Biotherapeutics by 15.7% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 18,477 shares of the biotechnology company stock valued at $ 291,000 after acquiring an additional 2,513 shares in the last quarter. Macquarie Group Ltd. lifted its stake in shares of Atara Biotherapeutics by 326.1% during the third quarter. Macquarie Group Ltd. now owns 3,311 shares of the biotechnology company stock worth $ 59,000 after buying an additional 2,534 shares during the period. Finally, ProShare Advisors LLC lifted its stake in shares of Atara Biotherapeutics by 9.5% during the fourth quarter. ProShare Advisors LLC now owns 31,414 shares of the biotechnology company stock worth $ 495,000 after buying an additional 2,717 shares during the period.
In other news, CFO Utpal Koppikar sold 5,582 shares of Atara Biotherapeutics stock in a transaction on Tuesday, May 17th. The stock was sold at an average price of $ 5.32, for a total value of $ 29,696.24. Following the completion of the sale, the chief financial officer now directly owns 207,592 shares of the company stock, valued at $ 1,104,389.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Pascal Touchon sold 13,913 shares of Atara Biotherapeutics stock in a transaction on Tuesday, May 17th. The shares were sold at an average price of $ 5.32, for a total value of $ 74,017.16. Following the completion of the sale, the chief executive officer now directly owns 486,313 shares of the company stock, valued at $ 2,587,185.16. The disclosure for this sale can be found here. In the last three months, insiders have sold 26,591 shares of company stock valued at $ 141,464. 4.00% of the stock is owned by insiders.
NASDAQ: ATRA opened at $ 5.14 on Friday. Atara Biotherapeutics, Inc. has a one year low of $ 4.61 and a one year high of $ 20.04. The stock has a market cap of $ 480.13 million, a PE ratio of -1.41 and a beta of 1.94. The stock has a 50 day moving average price of $ 6.89 and a 200 day moving average price of $ 11.78.
Atara Biotherapeutics (NASDAQ: ATRA – Get Rating) last posted its earnings results on Thursday, May 5th. The biotechnology company reported ($ 0.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($ 0.98) by $ 0.11. Atara Biotherapeutics had a negative return on equity of 122.18% and a negative net margin of 1,451.79%. During the same quarter in the previous year, the business earned ($ 0.86) earnings per share. As a group, sell-side analysts forecast that Atara Biotherapeutics, Inc. will post -3.45 EPS for the current year.
Several equities research analysts have recently commented on the stock. Citigroup downgraded shares of Atara Biotherapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $ 15.00 to $ 8.00 in a research note on Monday, May 9th. JPMorgan Chase & Co. reduced their target price on shares of Atara Biotherapeutics from $ 27.00 to $ 22.00 and set an “overweight” rating for the company in a report on Monday, March 28th. Canaccord Genuity Group reduced their target price on shares of Atara Biotherapeutics from $ 78.00 to $ 67.00 in a report on Tuesday, March 1st. StockNews.com cut shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 17th. Finally, The Goldman Sachs Group cut their target price on shares of Atara Biotherapeutics from $ 5.00 to $ 4.00 and set a “sell” rating for the company in a report on Tuesday, May 24th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $ 26.88.
About Atara Biotherapeutics: (Get Rating)
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma.
Featured Stories:
Want to see what other hedge funds are holding ATRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atara Biotherapeutics, Inc. (NASDAQ: ATRA – Get Rating).
Receive News & Ratings for Atara Biotherapeutics Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Atara Biotherapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.
.